MicroRNA-151a-3p Functions in the Regulation of Osteoclast Differentiation: Significance to Postmenopausal Osteoporosis

References

• Giusti A, Papapoulos SE. Bisphosphonates for postmenopausal osteoporosis. Prim Metab Bone Dis Disord Min Metabolism. 2018: 545–552.
   Google Scholar
• Franic D, Verdenik IJ. Risk factors for osteoporosis in postmenopausal women – from the point of view of primary care gynecologist. Slov J Public Health. 2018;57(1):33–38. doi:10.2478/sjph-2018-0005
   Google Scholar
• Mignot MA, Taisne N, Legroux I, Cortet B, Paccou JJ. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int. 2017;28(12):3431–3438.28875236
   PubMed Web of Science ®Google Scholar
• Wu F, Zhou D, Shen G, Cui Y, Lv Q, Wei FJC. Association of VDR and OPG gene polymorphism with osteoporosis risk in Chinese postmenopausal women. Climacteric. 2019;22:208–212.30624097
   PubMed Web of Science ®Google Scholar
• Castrogiovanni P, Trovato FM, Szychlinska MA, Nsir H, Imbesi R, Musumeci G. The importance of physical activity in osteoporosis. From the molecular pathways to the clinical evidence. Histol Histopathol. 2016;31(11):1183–1194. doi:10.14670/HH-11-79327311988
   PubMed Web of Science ®Google Scholar
• Pichler K, Loreto C, Leonardi R, Reuber T, Weinberg AM, Musumeci G. RANKL is downregulated in bone cells by physical activity (treadmill and vibration stimulation training) in rat with glucocorticoid-induced osteoporosis. Histol Histopathol. 2013;28(9):1185–1196. doi:10.14670/HH-28.118523553492
   PubMed Web of Science ®Google Scholar
• Bandeira L, Bilezikian JP. Novel therapies for postmenopausal osteoporosis. Endocrinol Metab Clin. 2017;46(1):207. doi:10.1016/j.ecl.2016.11.001
   Google Scholar
• Radominski SC, Bernardo W, Paula APD, et al. Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Rev Bras Reumatol. 2017;57:S452–S466.
   PubMedGoogle Scholar
• Migliaccio S, Fornari R, Greco EA, Luigi LD, Lenzi A. New therapeutical horizons in the management of postmenopausal osteoporosis. Aging Clin Exp Res. 2013;25(1):S117–S119. doi:10.1007/s40520-013-0106-x24048905
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang L, Zheng S, et al. Osthole inhibits osteoclasts formation and bone resorption by regulating NF‐κB signaling and NFATc1 activations stimulated by RANKL. J Cell Biochem. 2019;120(9):16052–16061. doi:10.1002/jcb.2888631081953
   PubMed Web of Science ®Google Scholar
• Taguchi Y, Jin G, Inoue JI. NF-κB Signaling in Osteoclastogenesis. 2015.
   Google Scholar
• Kim RY, Seong Y, Cho TH, Lee B, Kim IS, Hwang SJ. Local administration of nuclear factor of activated T cells (NFAT) c1 inhibitor to suppress early resorption and inflammation induced by bone morphogenetic protein-2. J Biomed Mat Res Part A. 2018;106(5):1299–1310. doi:10.1002/jbm.a.36332
   Web of Science ®Google Scholar
• Li J, Li Y, Peng X, Li B, Hui Q, Chen YJ. In vivo analysis of the effects of CoCrMo and Ti particles on inflammatory responses and osteolysis. RSC Adv. 2018;8(10):5151–5157. doi:10.1038/s41598-018-23465-5
   Web of Science ®Google Scholar
• Park K, Gu D, Jin S, et al. Pueraria lobate inhibits RANKL-mediated osteoclastogenesis via downregulation of CREB/PGC1β/c-Fos/NFATc1 signaling. Am J Chin Med. 2017;45(8):1–20.28068838
   PubMed Web of Science ®Google Scholar
• Link JC, Hasin-Brumshtein Y, Cantor RM, et al. Diet, gonadal sex, and sex chromosome complement influence white adipose tissue miRNA expression. BMC Genomics. 2017;18(1):89. doi:10.1186/s12864-017-3484-128095800
   PubMed Web of Science ®Google Scholar
• Zhang Z, Han Y, Sun G, et al. MicroRNA-325-3p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by down-regulation of aquaporin 5. Cell Mol Biol Lett. 2019;24(1):1–15.30873211
   PubMed Web of Science ®Google Scholar
• Zhu H, Cao XX, Liu J, et al. MicroRNA‐488 inhibits endometrial glandular epithelial cell proliferation, migration, and invasion in endometriosis mice via Wnt by inhibiting FZD7. J Cell Mol Med. 2019;23:2419–2430.30729701
   PubMed Web of Science ®Google Scholar
• Cao Z, Moore BT, Wang Y, et al. MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis. PLoS One. 2014;9(5):e97098. doi:10.1371/journal.pone.009709824820117
   PubMed Web of Science ®Google Scholar
• Tang P, Xiong Q, Ge W, Zhang L. The role of microRNAs in osteoclasts and osteoporosis. RNA Biol. 2014;11(11):1355–1363. doi:10.1080/15476286.2014.99646225692234
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hao T, Zhang H, Wei P, Li X. Over-expression of miR-151a-3p inhibits proliferation and migration of PC-3 prostate cancer cells. Xi bao yu fen zi mian yi xue za zhi. 2018;34(3):247–252.29773107
   PubMedGoogle Scholar
• Zhang Y, Peng X, Yi L, et al. Evaluation of suitable reference genes for qRT-PCR normalization in strawberry (Fragaria × ananassa) under different experimental conditions. BMC Mol Biol. 2018;19(1):1–10.29351732
   PubMed Web of Science ®Google Scholar
• Swets M, Wouters A, Krijgsman D, et al. HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and Western blot analysis: its expression characteristics remain enigmatic. Clin Immunol. 2018;194:80–86. doi:10.1016/j.clim.2018.07.00530006120
   PubMed Web of Science ®Google Scholar
• Yeon LY, Byul KH, Won LJ, et al. The association between urine albumin to creatinine ratio and osteoporosis in postmenopausal women with type 2 diabetes. J Bone Metab. 2016;23(1):1–7.26981514
   PubMedGoogle Scholar
• Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause — global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199–215. doi:10.1038/nrendo.2017.18029393299
   PubMed Web of Science ®Google Scholar
• Rao SS, Hu Y, Xie PL, et al. Omentin-1 prevents inflammation-induced osteoporosis by downregulating the pro-inflammatory cytokines. Bone Res. 2018;6(2):9. doi:10.1038/s41413-018-0012-029619269
   PubMed Web of Science ®Google Scholar
• Li M, Luo R, Yang W, Zhou Z, Li C. miR-363-3p is activated by MYB and regulates osteoporosis pathogenesis via PTEN/PI3K/AKT signaling pathway. In Vitro Cell Dev Biol Animal. 2019;55(5):376–386. doi:10.1007/s11626-019-00344-5
   Web of Science ®Google Scholar
• Löfvall H, Newbould H, Karsdal MA, et al. Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes. Arthritis Res Ther. 2018;20(1):67. doi:10.1186/s13075-018-1564-529636095
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kokabu S, Nakatomi C, et al. The actin-binding protein PPP1r18 regulates maturation, actin organization, and bone resorption activity of osteoclasts. Mol Cell Biol. 2018;38(4):e00425.29158294
   PubMed Web of Science ®Google Scholar
• Jin D, Wu X, Yu H, et al. Systematic analysis of lncRNAs, mRNAs, circRNAs and miRNAs in patients with postmenopausal osteoporosis. Am J Translat Res. 2018;10(5):1498–1510.
   PubMed Web of Science ®Google Scholar
• Wong KC, Papaioannou AJ. Postmenopausal osteoporosis treatment update. Curr Treat Options Oncol. 2018;4(2):142–157.
   Google Scholar
• Zhao N, Han D, Liu Y, et al. DLX3 negatively regulates osteoclastic differentiation through microRNA-124. Exp Cell Res. 2016;341(2):166–176. doi:10.1016/j.yexcr.2016.01.01826836061
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao H, Chen J, et al. Interferon-β-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett. 2012;586(19):3255–3262. doi:10.1016/j.febslet.2012.06.04722771905
   PubMed Web of Science ®Google Scholar
• Wang C, He H, Jiang Y, Wang L, Xu YJ. Reduced miR-144-3p expression in serum and bone mediates osteoporosis pathogenesis by targeting RANK. Biochem Cell Biol. 2018;96:627–635.29334613
   PubMed Web of Science ®Google Scholar
• Mengelfrom J, Feddersen S, Halekoh U, et al. Circulating microRNAs disclose biology of normal cognitive function in healthy elderly people – a discovery twin study. J Hum Genet. 2018;26:1378–1387.
   Web of Science ®Google Scholar
• Perezsanchez C, Fontugalde P, Ruizlimon P, et al. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. Hum Mol Genet. 2018;27(5):875–890.29329380
   PubMed Web of Science ®Google Scholar
• Kang MR, Jo SA, Yoon YD, et al. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB. Marine Drugs. 2014;12(11):5643–5656. doi:10.3390/md1211564325421321
   PubMed Web of Science ®Google Scholar
• Perpétuo IP, Caetanolopes J, Vieirasousa E, et al. Ankylosing spondylitis patients have impaired osteoclast gene expression in circulating osteoclast precursors. Front Med. 2017;4:5.
   Web of Science ®Google Scholar
• Choi J, Choi SY, Lee SY, et al. Caffeine enhances osteoclast differentiation and maturation through p38 MAP kinase/Mitf and DC-STAMP/CtsK and TRAP pathway. Cell Signal. 2013;25(5):1222–1227. doi:10.1016/j.cellsig.2013.02.01523434822
   PubMed Web of Science ®Google Scholar
• Han SY, Kim YK. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression. Am J Chin Med. 2019;47(2):439–455. doi:10.1142/S0192415X1950022830827151
   PubMed Web of Science ®Google Scholar
• Qi DY, Perkins SL, Kling SJ, Russell RG. Divergent regulation of 1,25-dihydroxyvitamin D3 on human bone marrow osteoclastogenesis and myelopoiesis. J Cell Biochem. 1999;72(3):387–395.10022520
   PubMed Web of Science ®Google Scholar
• Chen K, Yuan Y, Wang Z, et al. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL‐induced NFATc1 activation. J Cell Physiol. 2019;234(5):6477–6488.30341897
   PubMed Web of Science ®Google Scholar
• Wan H, Qian TY, Hu XJ, Huang CY, Yao WF. Correlation of serum CCL3/MIP-1α levels with disease severity in postmenopausal osteoporotic females. Balkan Med J. 2018;35(4):320–325. doi:10.4274/balkanmedj.2017.116529666038
   PubMed Web of Science ®Google Scholar
• Mamolini E, Cervellati C, Greco P, et al. VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population. Gynecol Endocrinol. 2017;33:937–941.28488893
   PubMed Web of Science ®Google Scholar
• Zha L, He L, Liang Y, et al. TNF-α contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation. Biomed Pharmacother. 2018;102:369. doi:10.1016/j.biopha.2018.03.08029571022
   PubMed Web of Science ®Google Scholar
• Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478. doi:10.3389/fgene.2019.0047831156715
   PubMed Web of Science ®Google Scholar
• Qiao L, Li CG, Liu D. CircRNA_0048211 protects postmenopausal osteoporosis through targeting miRNA-93-5p to regulate BMP2. Eur Rev Med Pharmacol Sci. 2020;24(7):3459–3466. doi:10.26355/eurrev_202004_2080432329818
   PubMed Web of Science ®Google Scholar
• Liu S, Wang C, Bai J, et al. Involvement of circRNA_0007059 in the regulation of postmenopausal osteoporosis by promoting the microRNA-378/BMP-2 axis. Cell Biol Int. 2021;45(2):447–455. doi:10.1002/cbin.1150233200464
   PubMed Web of Science ®Google Scholar